efgartigimod PH20 SC + Prednisone
Phase 3Terminated 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bullous Pemphigoid
Conditions
Bullous Pemphigoid
Trial Timeline
Mar 22, 2023 → Mar 20, 2025
NCT ID
NCT05681481About efgartigimod PH20 SC + Prednisone
efgartigimod PH20 SC + Prednisone is a phase 3 stage product being developed by Argenx for Bullous Pemphigoid. The current trial status is terminated. This product is registered under clinical trial identifier NCT05681481. Target conditions include Bullous Pemphigoid.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05681481 | Phase 3 | Terminated |
| NCT05267600 | Phase 2/3 | Completed |
| NCT04598477 | Phase 3 | Terminated |
| NCT04598451 | Phase 3 | Completed |
Competing Products
8 competing products in Bullous Pemphigoid
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab | Eli Lilly | Phase 2 | 52 |
| Benralizumab + Placebo | AstraZeneca | Phase 3 | 77 |
| QGE031 + Placebo | Novartis | Phase 2 | 52 |
| Azathioprine or Mycophenolate mofetil | Roche | Phase 2 | 52 |
| dupilumab + Matching Placebo + Oral corticosteroids (OCS) | Sanofi | Phase 2/3 | 64 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| BIV009 | Sanofi | Phase 1 | 32 |
| efgartigimod PH20 SC + Prednisone | Argenx | Phase 2/3 | 62 |